QIA.DE · Qiagen N.V.

DAX · XETRA

Risiko 5/10 · Diagnostics Post-COVID Reset · €36.69 ▲ 0.47%

Kennzahlen

• Price €36.69
• Market cap €7.6B
• P/E (ttm) 21.33
• Div yield 0.84%
• 52-wk range €27.56 – €47.59

Wichtigste Risiken

• COVID revenue tail-off exceeding non-COVID growth (Revenue growth credibility) — HIGH
• Competition from Roche/Thermo Fisher in sample prep (Market share & pricing power) — MED
• Biotech/pharma customer spending cuts (QIAsymphony and MDx instrument pull-through) — MED
• Thermo Fisher take-private speculation overhang (Strategic uncertainty) — LOW

Fazit

Solid niche platform but the post-COVID revenue reset makes near-term growth visibility low; non-COVID acceleration is the key re-rating catalyst.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.